A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug–Drug–Gene Interaction P
Bewertung der Expertengruppe Off-Label Infektiologie mit Schwerpunkt HIV / AIDS zu Cotrimoxazol (Trimethoprim/Sulfamethoxazol)
A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug–Drug–Gene Interaction P
![Pharmaceutics | Free Full-Text | A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug–Drug–Gene Interaction Predictions | HTML Pharmaceutics | Free Full-Text | A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug–Drug–Gene Interaction Predictions | HTML](https://www.mdpi.com/pharmaceutics/pharmaceutics-12-01074/article_deploy/html/images/pharmaceutics-12-01074-g006.png)
Pharmaceutics | Free Full-Text | A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug–Drug–Gene Interaction Predictions | HTML
![Pharmaceutics | Free Full-Text | A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug–Drug–Gene Interaction Predictions | HTML Pharmaceutics | Free Full-Text | A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug–Drug–Gene Interaction Predictions | HTML](https://www.mdpi.com/pharmaceutics/pharmaceutics-12-01074/article_deploy/html/images/pharmaceutics-12-01074-g001-550.jpg)